Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Voreloxin is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity. Phase 2.
Description | Voreloxin is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity. Phase 2. |
In vitro | Suprofen inactivates the diclofenac-4-hydroxylase activity of baculovirus-expressed P450 2C9 in a time- and concentration-dependent manner, which is consistent with mechanism-based inactivation. [1] Suprofen is a known generator of singlet oxygen whose participation in the reaction is supported by the effects of quenchers and scavengers. Suprofen photosensitizes the production of alkali-labile cleavage sites in DNA much more efficiently than direct strand breaks. [2] Suprofen sensitizes photo-oxidation of cholesterol, producing 7 alpha- and 7 beta-hydroperoxides but not 5 alpha-hydroperoxide of cholesterol. Suprofen-sensitized photo-oxidation of membrane lipids of liposomes increases leakage of trapped glucose, suggesting photosensitized destabilization of the membrane structure. [3] Suprofen incorporation in the phosphatidylcholine (PC) evaporation vesicles (REV) membrane leads to approximately 5% increase in the encapsulation efficiency (34%) in comparison to standard REV (29%). [4] |
Synonyms | AG 7352, Vosaroxin, SNS-595 |
Molecular Weight | 401.44 |
Formula | C18H19N5O4S |
CAS No. | 175414-77-4 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 20 mg/mL (49.82 mM), warmed
H2O: <1 mg/mL
Ethanol: <1 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Voreloxin 175414-77-4 DNA损伤和修复 凋亡 Apoptosis Topoisomerase AG-7352 Vosaroxin inhibit AG7352 SNS-595 AG 7352 SNS 595 Inhibitor SNS595 inhibitor